	***			-	···					
Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known						
				Application Number			10/578,590			
				Int'l. Filing Date			04 November 2004			
				First Named Inventor			Long			
				Group Art Unit			1643			
				Examiner Name			To Do Assisped			
(Use as many sheets as necessary) Sheet 1 of 1				Attorney Docket Number			To Be Assigned 035784/311260			
Silve	<u> </u>	01 1		Auditicy Docket Number 033/84/311200						
U. S. PATENT DOCUMENTS										
,		Document Number	. 3. 1	PAILNI D		JIVIE I A	.3			
Examiner	Cite	1		Publication Date MM-DD-YYYY A		Name	of Patentee or	- -	nns, Lines, Where	
Initials*	No.	No. Number - Kind Code (if known)				Applicant of Cited Document		Relevant Passages of Relevant Figures Appear		
								Аррсаі		
			L					į		
		FOR	EIG	SN PATENT	r DC	CUME	ENTS			
_		Foreign Patent Document	1					Pages, Column	1	
Examiner Initials	Cite			Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Lines, When Relevant	Dangaago	
Initials	No.							Passages or	I ATTACHED	
								Relevant Figu	res	
		XXXO 00 /0 4001 4 1						Appear		
	8 WO 02/04021 A1		1	01-17-2002		IDEC Pharmaceuticals				
						Corpo	ration			
	9	WO 02/22212 A2		03-21-2002		IDEC	Pharmaceuticals			
						Corporation				
	10	WO 03/029296 A1		04-10-2003		Chiron Corporation				
						————	1 Corporation			
			<u></u>							
			;							
			·							
	 					1				
			$\mathbf{O}_{\mathbf{I}}$	THER DOC	TIM	ENTS				
									English Language	
				TIAL LETTERS), title of the artice (when appropriate), title of the Translation						
Examiner	Cite	publisher, city and/or country when	ne, journal, serial, symposium, catalog, etc.), date, page(s), volumeissue number(s), or country where published. Attached							
Initials*	No.	parameter, every action of the control of the contr		paonona.						
1	FUNAKOSHI, S., et al., "Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B- Cell Lymphomas," Journal of Immunology, 1996, Vol. 19, No. 2, pp. 93-101.									
I										
4444449748117871484781871-4056488394000187874[4.4.										
	12 MALONEY, D.G., et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma," Journal of Clinical Oncology,									
I										
		1997, Vol. 15, No. 10, pp. 3266-3274.								
Examiner		1 100 7, 101. 10, 10. 10, pp. 5	200	327-1.			Date			

Considered

Signature

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.